An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis.
An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis.
An open label phase 3 study
Subjects from both INSPIRE 1 (TILD-19-07) and INSPIRE 2 (TILD-19-19) studies to roll over into this INSPIRE LTE study (TILD-21-01).
Inclusion Criteria:
Exclusion Criteria:
Bangalore, Tamil Nadu 560010, India
Sevilla, 41014, India
Shinjuku-ku, Tokyo 160-0023, Japan
Itabashi-ku, 173-8606, Japan